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Review of Hypoparathyroidism
Ejigayehu G. Abate1* and Bart L. Clarke2
1 Division of Endocrinology and Metabolism, Mayo Clinic, Jacksonville, FL, USA, 2 Division of Endocrinology, Diabetes, 
Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, USA
Hypoparathyroidism is a rare endocrine disorder in which parathyroid hormone (PTH) 
production is abnormally low or absent, resulting in low serum calcium and increased 
serum phosphorus. The most common cause of hypoparathyroidism is parathyroid 
gland injury or inadvertent removal during thyroid surgery. Current treatments include 
supplementation with calcium and active vitamin D, with goal albumin-corrected serum 
calcium level in the low-normal range of 8–9 mg/dl. Complications of the disease include 
renal dysfunction, nephrocalcinosis, kidney stones, extracellular calcifications of the 
basal ganglia, and posterior subcapsular cataracts, as well as low bone turnover and 
increased bone density. Until January 2015, hypoparathyroidism was the only classic 
endocrine disease without an available hormone replacement. Recombinant human PTH 
1-84, full-length PTH, is now available for a selected group of patients with the disease 
who are not well controlled on the current standard therapy of calcium and active vitamin 
D. In addition, the role of PTH replacement on quality of life, intracerebral calcifications, 
cataracts, improving bone turnover, and reduction of renal complications of the disease 
remains to be further investigated.
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iNTRODUCTiON
The mechanism of action of parathyroid hormone (PTH) was first described by Collip et al. in 1912 
(1, 2) when parathyroidectomized dogs who developed tetany were given purified oxen (bovine) 
PTH with resolution of symptoms. He concluded that PTH plays an important role in maintain-
ing normal blood calcium and phosphorus levels in the body. The full sequence of PTH was later 
described (2, 3).
Parathyroid glands are very small glands of the endocrine system, normally weighing approxi-
mately 25 g, and typically located to the side and behind the thyroid gland. Most individuals have 
four parathyroid glands, but rarely additional neck or ectopic parathyroid glands may be discovered 
during imaging or surgery. The role of these glands normally is to regulate calcium levels in the blood 
by release of PTH by sensing low serum calcium level through calcium-sensing receptors (CaSRs) 
located on the parathyroid cells. The serum calcium level is monitored and regulated tightly.
Parathyroid hormone regulates calcium homeostasis by a tightly controlled system. PTH plays 
an important role in mobilizing calcium from the skeleton where calcium is primarily stored and 
increasing calcium absorption from the intestine by increasing synthesis of calcitriol (1,25-dihy-
droxyvitamin D) from the kidney. Increased conversion of 25-hydroxyvitamin D to 1,25-dihydroxy-
vitamin D occurs in the proximal renal tubule. PTH also increases calcium reabsorption from the 
thick ascending limb of nephrons and facilitates the excretion of phosphorus through the kidneys.
Calcium is sensed by the CaSR, a 7-transmembrane G protein-coupled receptor found on the 
parathyroid glands, which stimulates PTH release in response to low serum calcium, and suppresses 
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PTH release in response to high serum calcium. The CaSR is 
also expressed in several other tissues including renal tubular 
cells, where it regulates calcium reabsorption, as well as bone 
and intestinal cells. In hypercalcemia, the filtered calcium load 
overcomes the renal tubular ability to reabsorb calcium resulting 
in decrease in calcium and sodium transport in the loop of Henle 
with an associated decrease in urinary concentrating ability to 
reduce calcium absorption through the kidneys.
When the production of PTH is reduced or absent, low PTH 
is inadequate to maintain normocalcemia and normophos-
phatemia, thus the biochemical findings of the disease, such as 
hypocalcemia, hyperphosphatemia, and low PTH ensue. The 
most common cause of hypoparathyroidism is inadvertent 
damage to the parathyroid glands during thyroid surgery (4–6). 
Other causes of hypocalcemia that need to be ruled out include 
magnesium deficiency and vitamin D deficiency. Magnesium 
is needed for the secretion of PTH by the parathyroid glands 
and its depletion or excess may cause hypoparathyroidism and 
subsequent hypocalcemia. This is thought to be due to the lack or 
excess magnesium playing a role in defective cyclic AMP genera-
tion in the parathyroid glands interfering with PTH synthesis and 
secretion (7).
Symptoms of hypoparathyroidism are the result of low serum 
calcium effect on the internal organs and correlate strongly with 
the acuteness of the low serum calcium as well as the absolute 
level. For example, a patient who has chronic hypoparathyroidism 
since childhood may adapt to low levels of calcium even as low 
as 7.0  mg/dl and remain asymptomatic. Presenting symptoms 
are variable. Mild symptoms include numbness and tingling of 
the extremities and perioral region, muscle cramps, and fatigue, 
and in severe cases, tetany, seizure, altered mental status, cardiac 
rhythm disturbances, refractory congestive heart failure, bron-
chospasm, and laryngospasm can be seen (8, 9). In most patients, 
symptoms develop when the albumin-corrected serum calcium is 
less than 7.5–8.0 mg/dl (7).
PRevALeNCe
Epidemiologic studies estimate the incidence of hypopar-
athyroidism in the U.S. to 24–37/100,000 person-years, with 
an estimate of 60,000–80,000 affected individuals (10–12). 
Overall, 75% of cases are female and 25% male (13). About 
75% of these patients are aged 45  years or older, and roughly 
75% of cases are due to neck surgery and 25% are reported 
to be due to non-surgical causes. The most common cause of 
hypoparathyroidism is anterior neck surgery, i.e., secondary to 
thyroid or parathyroid or head or neck cancer surgery, which 
is reported to occur in 7–36% of surgeries, of which 38% are 
due to total thyroidectomy, 21% parathyroidectomy, 9% partial 
thyroidectomy, and 5% other neck surgeries (13). Most have 
transient hypoparathyroidism where parathyroid function 
recovers fully within in 6  months, and only 1–5% of patients 
develop permanent hypoparathyroidism lasting longer than 
6 months (4, 13–16). Risk of hypoparathyroidism after anterior 
neck surgery depends on the experience of the surgeon. In 
addition, other factors that increase risk of hypoparathyroidism 
after neck surgery including, multigland parathyroid disease 
where more than one gland is removed, long-standing history 
of hyperparathyroidism resulting in hungry bone syndrome 
and in malabsorption resulting from weight loss surgeries [in 
particular roux-en-y gastric bypass surgery where absorption of 
calcium and vitamin D is affected (4)]. Vitamin D deficiency 
prior to surgery can result in postoperative hypocalcemia as 
well, and most experts recommend replacement of vitamin 
D to maintain vitamin D level in sufficient range (>20  ng/
dl) prior to surgery. Vitamin D level should be individualized 
and corrected with caution in those individuals with primary 
hyperparathyroidism undergoing parathyroidectomy to prevent 
risk of hypercalcemia. The optimal 25-hydroxyvitamin D level 
is unknown in these individuals but some studies have shown a 
correlation between size of parathyroid adenoma and vitamin D 
deficiency (17).
Inherited causes of hypoparathyroidism are summarized in 
Table 1. Other rare, non-hereditary causes of hypoparathyroidism 
include parathyroid gland destruction such as irradiation and 
infiltrative disease (hemochromatosis, Wilson’s disease, granulo-
mas, or metastatic cancer). In addition, neonatal hypocalcemia 
of prematurity or secondary to maternal hypercalcemia, hypo- 
or hypermagnesemia, and calcium sensor receptor antibodies. 
Pseudohypoparathyroidism (PTH resistance of kidney and bone 
presenting with high PTH and low calcium) is a separate disorder 
that can be seen rarely.
CLiNiCAL MANiFeSTATiONS
Physical examination of a patient with hypocalcemia includes 
assessment of neuromuscular hyperexcitability by testing for 
Chvostek’s and Trousseau’s signs. Chvostek’s sign is elicited by 
tapping the facial nerve in front of the ear, causing the facial mus-
cles on the ipsilateral side to twitch, causing contractions ranging 
from the upper lip and nose to the entire half-face when severe and 
significant hypocalcemia is present. Chvostek’s sign is positive in 
15% of individuals with normal serum calcium. Trousseau’s sign 
is elicited by placing a blood pressure cuff around the arm and 
inflating the cuff to greater than the systolic pressure and holding 
this in place for 3 min, thereby occluding the brachial artery. The 
combination of absence of blood flow and hyperexcitability of 
the muscles due to hypocalcemia results in painful flexion of 
the wrist and metacarpophalangeal joints, with extension of the 
distal interphalangeal and proximal interphalangeal joints, and 
abduction of the fingers.
Clinical symptoms correlate with acuteness of hypocalcemia, 
as well as the absolute level of serum calcium. Patients with an 
acute drop in their serum calcium after neck surgery have more 
dramatic symptoms than those with chronic hypocalcemia. 
Myoclonic jerks, twitching, new-onset seizures due to cerebral 
hypocalcemia, or worsening of seizures are neurologic manifesta-
tions of hypocalcemia. Cardiac manifestations are prolonged QT 
interval and T-wave alternans, acute cardiomyopathy, and con-
gestive heart failure due to decreased cardiac contractility related 
to low serum calcium and possibly PTH deficiency, as there are 
PTH receptors in cardiac myocytes.
Patients with hypoparathyroidism typically have higher bone 
density due to low bone turnover (6, 8, 18–20). Markers of bone 
TAbLe 1 | inherited causes of hypoparathyroidism.
Disease inheritance Gene/protein Chromosomal 
abnormalities
Associated findings
Syndromic forms
Autoimmune polyglandular 
syndrome type 1 (APS-1)
Autoimmune recessive AIRE gene 
mutation
21q22.3 Addison’s disease, pernicious anemia, diabetes mellitus type I, 
hypoparathyroidism, candidiasis, primary hypogonadism, autoimmune 
thyroid disease, alopecia, vitiligo
DiGeorge type I Autosomal dominant TBX1, NEBL 22q1.2/tbx1 Conotruncal abnormalities, abnormal facies, thymic aplasia, cleft palate, 
hypocalcemia, immunodeficiency, congenital heart defect, deformities of 
the ear, nose, and mouth
CHARGE Autosomal dominant CHD7, SEMA3E 8q12.1–
q12.2,7q21.11
Coloboma of the eye, heart malformation, choanal atresia, retardation 
of growth and development, and genital and ear abnormalities, 
gonadotropin deficiency, anosmia
Hereditary deafness and renal 
dysplasia syndrome (HDR)
Autosomal dominant GATA3 10p14 Deafness, renal dysplasia
Kenny–Caffey syndrome type I, 
Sanjad–Sakati syndrome
Autosomal dominant/
recessive
TBCE 1q42.3 Short stature, osteosclerosis, cortical thickening of long bones, delayed 
anterior fontanel closure, basal ganglia calcification, hyperopia
Kenney–Caffey syndrome 
type 2
Autosomal recessive FAM111A 11q12.1
Dubowitz syndrome Autosomal recessive Unknown ? Microcephaly, short stature, abnormal faces, and mild to severe mental 
retardation
Bartter syndrome type 5 Autosomal dominant CaSR 3q21.1 May be accompanied by hypokalemia and metabolic alkalosis
Nephropathy, nerve deafness Autosomal dominant Unknown ?
Nerve deafness without renal 
dysplasia
Autosomal dominant Unknown ?
Kearns–Sayre syndrome
MELAS
MTPDS
Maternal Mitochondrial 
genome
? Muscle defect: ophthalmoplegia, proximal muscle weakness, bilateral 
pigmented retinopathy, cardiac conduction abnormality, cerebral ataxia, 
deafness, diabetes mellitus, growth hormone deficiency, short stature
Non-syndromic
Isolated hypoparathyroidism Autosomal dominant PTH, GCMB 11p15,6p24.2
Autosomal recessive 
X-linked
SOX3 Xq26–27
ADH1 Autosomal dominant CaSR 3q21.1 Hypocalcemia, hypercalcuria, normal or low PTH, low magnesium
ADH2 Autosomal dominant GNA11 19p13
AIRE, autoimmune regulator 1; GCM2, glial cell missing 2; CaSR, calcium-sensing receptor; TBX1, T-box 1; NEBL, nebulette; CHD7, chromodomain helicase DNA-binding protein 
7; SEMA3E, semaphorin 3E; GATA3, GATA-binding protein 3; TBCE, tubulin folding cofactor E; FAM111A, family with sequence similarity 111 member A; GCMB, glial cell missing 
gene; SOX3, Sry-related HMG box; GNA11, G protein subunit alpha 11; ADH, autosomal dominant hypocalcemia; MELAS, mitochondrial encephalopathy, stroke like episodes and 
lactic acidosis; MTPDS, mitochondrial trifunctional protein deficiency syndrome; ?, unknown.
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turnover and iliac crest bone biopsy show a reduction in indices 
of bone turnover associated with an increase in trabecular and 
cortical width and density (21). Despite the higher bone density 
seen in these patients, the risk of fractures is not yet certain, 
although one study showed increased risk of upper extremity 
fracture in non-surgical hypoparathyroidism (11).
Impaired renal function is the most common complication 
seen in patients treated for hypoparathyroidism. It is associated 
with the age of the patient, duration of the disease, and level 
of hypercalcemia during treatment. Absence of PTH results 
in inability of renal tubules to reabsorb calcium, resulting in 
hypercalciuria and nephrocalcinosis. In addition, patients with 
underlying renal disease such as renal dysgenesis in DiGeorge 
syndrome are in particular at higher risk for nephrolithiasis. 
Overtreatment of hypoparathyroidism with calcitriol and calcium 
can lead to nephrolithiasis, thus monitoring of renal calcium 
excretion is necessary. One study found rates of chronic kidney 
disease Stage 3 or higher were 2- to 17-fold higher in patients 
with hypoparathyroidism than in normal individuals followed 
for 7  years (22). In addition, 50% of hypoparathyroid patients 
in this cohort had increased 24-h urine calcium and 25% had 
frank hypercalcuria. In patients who had renal imaging, 31% had 
nephrocalcinosis on CT scan or ultrasound of the kidneys, and 
2–17% had renal impairment (5). Risk of hospitalization related 
TAbLe 2 | Calcium and vitamin D metabolites in the management of 
chronic hypoparathyroidism.
Medication Typical dose
Calcium carbonate 1,000–9,000 mg elemental calcium/day 
in 2–4 divided doses
Calcium citrate 1,000–9,000 mg elemental calcium/day 
in 2–4 divided doses
vitamin D preparation
Ergocalciferol (D2) or cholecalciferol (D3) Total 25-hydroxyvitamin D  
level ≥30 ng/ml
Calcitriol [1,25(OH)2D3] 0.25–2.0 μg/day
Alfacalcidol (1-alphaOH-vitamin D3) 0.5–4.0 μg/day (not available in U.S.)
Thiazide diuretics/other
Hydrochlorothiazide 12.5–100 mg/day
Chlorthalidone 25–100 mg/day longer duration
Indapamide 1.25–5 mg/day
Amiloride 5 mg daily (alone or combined with 
hydrochlorothiazide)
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to renal causes (kidney stones or chronic kidney disease) was 
higher in adult hypoparathyroid patients than normal controls 
(23). The same has been reported in children (24).
Many patients complain of cognitive dysfunction, in particu-
lar, brain fog, fatigue, and easy fatigability (9). Higher incidence 
of anxiety, depression, and overall reduced quality of life occurs 
in patients with hypoparathyroidism compared to normal control 
groups (8, 25, 26). However, one systematic review failed to show 
a link between PTH and cognitive dysfunction and dementia 
(27), so it is assumed that these conditions are mostly due to the 
calcium disturbance.
Recent studies have shown an increased risk of posterior 
subcapsular cataracts, likely due to elevated calcium × phospho-
rus product occurring in lenses in the eyes. Basal ganglia and 
intracerebral calcifications may be associated with extrapyrami-
dal movement disorders and psychosis, but not all studies have 
confirmed an association. Increased risks of cardiac arrhythmias 
and cardiovascular diseases have also been reported (11, 22, 23). 
Other studies have suggested an increased incidence of infection 
in these individuals, although the mechanism is not clear (11).
biOCHeMiCAL FeATUReS
Albumin-corrected serum calcium and 1,25(OH)2D are typically 
low, with an increased serum phosphorus level. Intact PTH is 
typically low but can be inappropriately normal for the degree 
of hypocalcemia. Twenty-four-hour urine calcium is most often 
increased, but may be normal or low before calcium supplemen-
tation is started, depending on calcium intake and bone turnover 
(28). Measurement of 25-hydroxyvitamin D, magnesium, and 
kidney function are critical in helping to understand the physiol-
ogy of individuals affected by hypoparathyroidism.
PHYSiCAL eXAMiNATiON
Physical examination includes an examination of the neck for 
scars that might suggest postsurgical hypoparathyroidism, 
evaluation for mucocutaneous candidiasis, or vitiligo that 
may suggest autoimmune polyglandular syndrome type 1, and 
generalized bronzing and signs of liver disease that may suggest 
hemochromatosis or other causes of iron overload. In addition, 
growth retardation, congenital anomalies, hearing loss, or mental 
retardation suggest the possibility of genetic syndromic causes of 
the disease.
TReATMeNT
Conventional Therapy
Careful surgical planning in patients with hyperparathyroidism 
with preoperative localization of the parathyroid tumor may 
reduce the likelihood of postoperative parathyroid gland 
dysfunction. If an extensive surgical procedure is undertaken, 
preservation with reimplantation of parathyroid tissue should be 
done. Presurgical optimization of vitamin D is helpful, given that 
vitamin D deficiency is very common in the older population and 
patients undergoing parathyroid surgery. Caution with vitamin D 
replacement prior to surgery is appropriate due to concerns that 
too much vitamin D could worsen hypercalcemia. Studies have 
shown that vitamin D supplementation improves bone health in 
these individuals (4).
To date, three guidelines on the management of hypoparathy-
roidism have been published, including those of the International 
Consensus Conference guidelines based on the first international 
conference on hypoparathyroidism held in Florence, Italy, in May 
2015, the European Society of Endocrinology clinical guidelines, 
and the American Association of Clinical Endocrinologists and 
American College of Endocrinology Disease State Clinic Review 
(4, 16, 29). In addition, three papers were published in 2016 
on presentation, epidemiology, diagnosis, and management of 
hypoparathyroidism (6, 12, 30). These guidelines address man-
agement of acute and chronic hypoparathyroidism. Long-term 
management of hypoparathyroidism should target goal serum 
calcium within the low-normal range, with serum phosphorus 
within the high-normal range, and avoid significant hypo- or 
hypercalcemia. The goal is to reduce symptoms, minimize risk 
of kidney stones and kidney dysfunction, and prevent ectopic 
soft tissue calcium deposition. With low or absent PTH, calcium 
absorption is dependent on daily calcium and active vitamin D 
intake, so patients with hypoparathyroidism require daily con-
sistent calcium and active vitamin D intake necessary to achieve 
goal serum calcium. Intake of other medications such as iron can 
interfere with calcium absorption.
The goal of therapy is to maintain serum calcium level at 
8.0–9.0 mg/dl range while normalizing urinary calcium. Standard 
treatment consists of adequate calcium, vitamin D2 or D3, active 
vitamin D (1,25-dihydroxyvitamin D3), and magnesium sup-
plementation as needed (Table 2). High doses of vitamin D2 or 
Vitamin D3 supplementation may increase action of vitamin D 
and vitamin D may also have extraskeletal effects in some tissues. 
Calcium carbonate (containing 40% elemental calcium) and cit-
rate (containing 21% elemental calcium) are the most commonly 
prescribed preparations given, typically in divided doses two to 
four times per day. For patients who have hypo- or achlorhydria 
due to use of antacids or proton pump inhibitor therapy, or 
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elderly patients with low gastric acid secretion, calcium citrate is 
the preferred preparation for the management of hypocalcemia 
because calcium carbonate requires an acidic gastric environ-
ment for digestion and absorption, whereas calcium citrate is 
easily absorbed without stomach acid. Calcium carbonate should 
be taken with food, unlike calcium citrate, which does not require 
food intake to absorb. Magnesium supplementation may be nec-
essary if serum magnesium is low, as normal serum magnesium 
is required for normal secretion of PTH (31). Twenty-four-hour 
urine calcium and creatinine should be monitored every 6 months 
to once a year to monitor for hypercalcuria. Thiazide-type diuret-
ics (hydrochlorothiazide, chlorthalidone, and indapamide) and 
sodium restriction may be added to reduce urine calcium if 
hypercalcuria is present.
Despite standard therapy, some individuals remain symp-
tomatic or fail to meet treatment goals, with some requiring 
multiple hospitalizations for the treatment of hypocalcemia or 
complications of hypocalcemia. For those patients with difficult 
to control hypoparathyroidism, new adjunctive therapy options 
are available (29, 30).
eMeRGiNG TReATMeNTS
PTH 1-34
Teriparatide (PTH 1-34) is a truncated molecule of synthetic 
PTH approved for management of osteoporosis, but not 
hypoparathyroidism. PTH 1-34 has been evaluated in a num-
ber of studies in adult and pediatric patients with postsurgical 
hypoparathyroidism (32) and permanent hypoparathyroidism 
from other causes (33–38) and appears to be safe and efficacious. 
Urinary calcium in PTH 1-34 treated patients was decreased 
when injections were given once a day compared to calcitriol-
treated controls (35, 37). In a study of 14 children treated with 
twice a day PTH 1-34 for 28 weeks vs. once a day injection, serum 
calcium, serum magnesium, and urine calcium parameters were 
better controlled in the twice daily injection group compared to 
the once daily treatment group, especially in the second half of 
the day (12–24 h) (35). When PTH 1-34 was given by an insulin 
pump as a continuous infusion, urine calcium was reduced by 
50%, and serum calcium was near normal, with minimal fluc-
tuation compared to twice daily injections (38). Improvement 
in mental and physical health has been reported with PTH 1-34 
treatment (39).
Recombinant Human Parathyroid 
Hormone (rhPTH) 1-84
The full-length form of rhPTH (1-84; Natpara) was the first 
approved form of PTH approved by the FDA in January 2015 
for adjunctive therapy in management of hypoparathyroidism 
in individuals not adequately controlled with calcium, active 
vitamin D, thiazide-type diuretics, and/or magnesium therapy as 
needed. Natpara is given as a once a day subcutaneous injection 
based on phase 1 clinical trial data in adults with hypoparathy-
roidism showing that single daily injections caused improvement 
in serum calcium for 24 h (40). rhPTH 1-84 initially was evalu-
ated for management of osteoporosis and approved in Europe in 
2006, but due to increased risk of hypercalcemia in the U.S. trial, 
the FDA declined to approve it.
An open-label trial of 27 patients treated with rhPTH 1-84 
every other day at 100 μg/dose for 4 years showed that all patients 
had stable serum calcium and were able to reduce their calcium 
and active vitamin D supplementation significantly (41). Twenty-
four-hour urine calcium was also reduced at 4 years with treat-
ment, and serum phosphorus declined (41). Six-year data from 
this cohort was recently published, extending these findings (42). 
The long-term efficacy of PTH replacement therapy on kidney 
function preservation is not yet known.
REPLACE was, the pivotal randomized, double-blind, 
placebo-controlled trial for 24 weeks conducted with 134 adults 
with hypoparathyroidism randomized 1:2 to placebo or rhPTH 
1-84. Subjects were injected once daily with rhPTH 1-84 vs. 
placebo with dose titration from 50 to 75 or 100 μg/day (5). The 
trial showed that 53% of treated subjects were able to reduce their 
supplemental calcium and active vitamin D doses by ≥50%, with 
43% able to completely stop all active vitamin D and reduce their 
calcium dose to 500 mg/day or less, while maintaining normal 
serum calcium.
Markers of bone turnover are typically reduced, reflect-
ing low bone turnover, along with higher bone density due to 
increased trabecular and cortical bone volume, in individuals 
with untreated hypoparathyroidism, but it is not yet clear whether 
this denser bone translates into increased bone strength (18, 41). 
Treatment with rhPTH 1-84 increased lumbar spine BMD, but 
did not change femoral neck or total hip BMD, whereas the one-
third distal radius BMD declined at 2 years but remained stable at 
4 years (41). Paired transiliac bone biopsies before and after treat-
ment with rhPTH (1-84) showed that 1 year treatment resulted 
in reduction in bone mineralization and high bone turnover, but 
these parameters returned to baseline at 2 years (43, 44).
At baseline, hypoparathyroidism patients have low to low-
normal bone turnover markers, and with treatment with rhPTH 
(1-84), there was a threefold increase in markers of bone resorp-
tion [e.g., tartrate-resistant acid phosphatase 5b and collagen 
type 1 crosslinked C-telopeptide (CTx-telopeptide)], and bone 
formation markers (e.g., bone specific alkaline phosphatase, 
osteocalcin, and total procollagen type 1 N-terminal propeptide), 
peaking at 6–12 months, with a slow decline to steady state by 
30 months, but remaining higher than pretreatment values (41).
Quality of life among patients treated with rhPTH (1-84) 
100 μg every other day for 5 years assessed by the SF-36 showed 
an improvement compared to untreated individuals (45). On 
the contrary, there was no change in muscle strength, postural 
stability or quality of life at 6 months in the phase III randomized 
controlled trial of hypoparathyroid patients receiving rhPTH 
(1-84) (46).
Safety
Long-term data on the safety and efficacy of PTH in any form 
beyond 6 years is not available. In the REPLACE trial, a single 
subject taking PTH (1-84) 100 μg each day had hypercalcemia, 
which required dose reduction to 50 μg each day, and did not 
require discontinuation of treatment. Muscle spasm, hypocalce-
mia, paresthesia, headache, and nausea were the most common 
6Abate and Clarke Hypoparathyroidism, Hypocalcemia, PTH, Natpara
Frontiers in Endocrinology | www.frontiersin.org January 2017 | Volume 7 | Article 172
adverse events reported in those receiving rhPTH (1-84) com-
pared to placebo, most of which occurred during dose titration at 
the beginning of the study (5). Cusano et al. reported 11 episodes 
of mild hypercalcemia in eight subjects over 4 years of treatment 
with PTH (1-84) 100 μg every other day, most of which occurred 
within the first 6 months of treatment during dose titration, and 
corrected with adjustment of calcium and vitamin D intake (41).
Longer term studies are needed to address the potential safety 
concerns related to osteosarcoma seen in the Fisher 344 strain of 
rat treated with rhPTH 1-34 in preclinical studies, which was dose 
and treatment duration dependent (47). The U.S. post-marketing 
surveillance study of adults treated with teriparatide for over 
7 years did not report an association between rhPTH 1-34 treat-
ment and osteosarcoma in humans (48).
Long-term effects of Natpara are unknown. Given the lack of 
such data, it is recommended that rhPTH 1-84 be prescribed only 
for those patients who cannot be well controlled on calcium and 
active forms of vitamin D, and for whom the potential benefits are 
considered to outweigh the potential risks.
NPS Pharmaceuticals, Inc./Shire Pharmaceuticals has des-
ignated a Natpara REMS registry to monitor potential adverse 
effects of Natpara. Similar to rhPTH 1-34, Natpara has a black box 
warning to avoid use in those individuals with increased baseline 
risk of osteosarcoma including those with Paget’s disease of bone, 
unexplained elevation of serum calcium or alkaline phosphatase, 
pediatric and young adult patients with open epiphyses, patients 
with hereditary disorders predisposing to osteosarcoma, or 
patients with a history of prior external beam or implant radia-
tion therapy involving the skeleton.
FUTURe DiReCTiONS
Future therapeutic options include additional PTH analogs with 
different kinetics, administration of PTH via pump or implant-
able devices, parathyroid gland transplantation, or ultimately 
regeneration of parathyroid glands by stem-cell therapy.
CONCLUSiON
Hypoparathyroidism is no longer a rare disease without treat-
ment options. rhPTH 1-84 (Natpara) appears to be a promis-
ing treatment option for those individuals who are not well 
controlled on current standard therapy with calcium, active 
vitamin D, thiazide-type diuretics, and/or magnesium as 
needed. Additional studies are needed to evaluate if Natpara 
provides benefit in improving comorbidities and complica-
tions of hypoparathyroidism, including quality of life, neu-
ropsychiatric conditions, kidney dysfunction, kidney stones, 
extraskeletal calcifications, cataracts, and skeletal strength and 
fracture.
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